The antimicrobial peptide anoplin was identified as a potent new carrier for delivering peptide nucleic acid (PNA) antisense antibiotics into E. coli and Salmonella, with activity in the 2-4 μM range.
2-4 μMAntibacterial activity of anoplin-PNA conjugate against E. coli and S. Typhimurium using a non-cleavable linker
What the researchers found
Anoplin conjugated to PNA via a non-cleavable ethylene glycol linker demonstrated antibacterial activity against E. coli and S. Typhimurium at 2-4 μM, establishing it as an effective new PNA carrier peptide.
Why it matters
Antibiotic resistance is a global health crisis. Antisense PNA technology can target genes that are essential for bacterial survival, but delivery into Gram-negative bacteria has been a major bottleneck. Identifying effective carrier peptides like anoplin brings this technology closer to clinical application.
The numbers in context
Multiple linker types and stapled analogs tested against Gram-negative bacteria.
How the study worked
In vitro study testing peptide-PNA conjugates with different carrier peptides (anoplin, (KFF)₃K, and their stapled analogs) and linkers (non-cleavable eg1 vs. reducible disulfide) against various Gram-negative bacterial strains. PNA targeted acyl carrier protein mRNA.
Who was studied
In vitro testing against Gram-negative bacterial pathogens
What this study cannot tell us
In vitro testing only — no animal infection models. Limited to two Gram-negative species. The mechanism by which anoplin delivers PNA while stapled peptides fail is not fully explained. Cytotoxicity to human cells was not comprehensively assessed.
How to read the evidence
Preliminary evidence from in vitro experiments. Demonstrates proof of concept for anoplin as a PNA carrier but lacks in vivo validation.
When this study was published
Published in 2024. Contributes to the active field of peptide-based antimicrobial delivery.
The bigger picture
As traditional antibiotics fail against resistant bacteria, antisense approaches offer a fundamentally different mechanism that bacteria may struggle to develop resistance against. The challenge has always been delivery. This work advances the toolkit of carrier peptides, moving peptide-PNA antibiotics closer to practical application.
Questions still open
- Why do stapled peptides penetrate membranes but fail as PNA carriers — is it a conformational issue?
- Would anoplin-PNA conjugates be effective in animal infection models?
- Can the anoplin carrier approach be extended to other antisense targets beyond acyl carrier protein?
Common questions
What are peptide nucleic acids and how do they fight bacteria?
Why is delivery such a challenge for PNA antibiotics?
Read the original research
Evaluating delivery of peptide nucleic acids to Gram-negative bacteria using differently linked membrane-active peptides and their stapled analogs.
Bioorganic & medicinal chemistry letters, 114, 129993
Citation
Siekierska, Izabela; Burmistrz, Michał; Trylska, Joanna. (2024). Evaluating delivery of peptide nucleic acids to Gram-negative bacteria using differently linked membrane-active peptides and their stapled analogs.. Bioorganic & medicinal chemistry letters, 114, 129993. https://doi.org/10.1016/j.bmcl.2024.129993